Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study aimed to elucidate early responses to Atez/B...

Full description

Bibliographic Details
Main Authors: Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kouji Joko, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan)
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Cancer Reports
Subjects:
albumin‐bilirubin score
atezolizumab plus bevacizumab
hepatic function
lenvatinib
unrespectable hepatocellular carcinoma
Online Access:https://doi.org/10.1002/cnr2.1464

Internet

https://doi.org/10.1002/cnr2.1464

Similar Items